ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review

September 2020 | 42 pages | ID: AD977A65B5BEN
GlobalData

Abstracts

ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ArQule Inc (ArQule) is a biopharmaceutical company that focuses on the research and development in the area of small molecules using Precision Medicine approach for the treatment of cancers and rare proliferative diseases. The company pipeline products include ARQ 531, a reversible inhibitor of wild type BTK and C481S-mutant BTK; Miransertib (ARQ 092), an inhibitor of protein kinase B (AKT); ARQ 751, a next generation small molecule, also an inhibitor of AKT and Derazantinib (ARQ 087), a multi kinase inhibitor of fibroblast growth factor receptor (FGFR). The company primarily operates in the US and has collaborative license agreements with Basilea Pharmaceutica Ltd and Sinovant Sciences Ltd for the development of its pipeline products. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc Key Recent Developments

Jan 17,2020: Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Dec 10,2019: Merck to acquire ArQule in $2.7bn deal
Oct 30,2019: ArQule reports third quarter 2019 financial results
Aug 07,2019: ArQule reports second quarter 2019 financial results
May 01,2019: ArQule reports first quarter 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ArQule Inc - Key Facts
ArQule Inc - Key Employees
ArQule Inc - Key Employee Biographies
ArQule Inc - Major Products and Services
ArQule Inc - History
ArQule Inc - Company Statement
ArQule Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
ArQule Inc - Business Description
ArQule Inc - SWOT Analysis
SWOT Analysis - Overview
ArQule Inc - Strengths
ArQule Inc - Weaknesses
ArQule Inc - Opportunities
ArQule Inc - Threats
ArQule Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
ArQule Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jan 17, 2020: Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Dec 10, 2019: Merck to acquire ArQule in $2.7bn deal
Oct 30, 2019: ArQule reports third quarter 2019 financial results
Aug 07, 2019: ArQule reports second quarter 2019 financial results
May 01, 2019: ArQule reports first quarter 2019 financial results
Mar 15, 2019: ArQule announces management team changes
Mar 07, 2019: ArQule reports fourth quarter and full year 2018 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ArQule Inc, Key Facts
ArQule Inc, Key Employees
ArQule Inc, Key Employee Biographies
ArQule Inc, Major Products and Services
ArQule Inc, History
ArQule Inc, Key Competitors
ArQule Inc, Ratios based on current share price
ArQule Inc, Annual Ratios
ArQule Inc, Annual Ratios (Cont...1)
ArQule Inc, Interim Ratios
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
ArQule Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ArQule Inc, Performance Chart (2014 - 2018)
ArQule Inc, Ratio Charts
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Spectrum Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Jubilant Therapeutics Inc
Incyte Corp
GlaxoSmithKline LLC
Curis Inc
Bristol-Myers Squibb Co
Array BioPharma Inc
Ariad Pharmaceuticals Inc
Aptose Biosciences Inc